In a first small series of aggressive pituitary adenomas and carcinomas retrospectively tested for MSH6 status, the positive response to TMZ treatment corresponded to a high immunoexpression of MSH6 [18]. This evidence concerns the gene MSH6 and pituitary gland adenoma.